Johnson & Johnson (NYSE:JNJ) lowered its full-year earnings outlook on Tuesday despite posting better-than-expected ...
KEY's third-quarter 2024 results rise on the back of higher revenues and a decline in expenses. However, a rise in provisions ...
We expect the company’s revenues to come in at $2 billion and adjusted earnings to be $1.60 per share, reflecting a top-line ...
Stock markets in the Gulf ended lower on Thursday as investors await more third-quarter earnings amid escalating geopolitical ...
Synovus Financial shares gained 3.1% after-hours as Q3 earnings beat expectations with increased net interest income and ...
See our interactive dashboard analysis on United Airlines’ FY 2024Q3 Earnings Preview for more details on United Airlines’ ...
Abbott Laboratories on Wednesday reported better-than-expected third-quarter earnings and sales, boosted by strength in the ...
Elevance Health reported Q3 revenue of $44.7 billion, driven by higher premium yields and CarelonRx growth. However, profit ...
Johnson & Johnson's innovative medicines division shows promise with expected revenues of $57bn by 2025. See more about JNJ ...